Who are FidoCure®'s investors?

FidoCure®'s investors include Andreessen Horowitz, Polaris Partners, Lerer Hippeau, TAU Ventures, Y Combinator Continuity Fund, Borealis Ventures.

When was FidoCure® founded?

FidoCure® was founded in 2016.

Where is FidoCure® headquartered?

FidoCure® is headquartered in Palo Alto, California, United States.

What industry is FidoCure® in?

FidoCure® operates in Healthcare, Oncology, Pets.

How many employees does FidoCure® have?

FidoCure® has 11-50 employees.

FidoCure®

FidoCure® is the leader in Precision Medicine for Canine Oncology.

Palo Alto, United States · Founded 2016

Healthcare

Oncology

Pets

YC W18

Headquarters: Palo Alto, California
Employees: 11–50
Founded: 2016
Business Model: B2B

Website: fidocure.com
Last Round: Series AOct 2020
Rounds: 2

About

Cancer is a genetic disease. We know this from decades of human and veterinary cancer research. Precision medicine and targeted therapies are successfully used to treat humans with cancer. At FidoCure®, we bring this approach to the world of veterinary medicine. FidoCure® empowers veterinarians to offer genetic sequencing and targeted therapies to treat dogs with cancer. We are committed to expanding the veterinary oncology toolbox for both diagnostics and therapeutics. Our veterinary partners have treated thousands of dogs over the past 30 years and work closely with the growing FidoCure® network of over 143 clinics and 180 forward-thinking veterinary oncologists throughout the US. Together, we can combat canine cancer!

Summary

FidoCure® is a Healthcare company based in Palo Alto, United States, founded in 2016. Its most recent funding was a Series A round in Oct 2020. Investors include Andreessen Horowitz, Polaris Partners and Lerer Hippeau.

LinkedIn X (Twitter)